摘要
目的评价抗胸腺球蛋白(ATG)联合环孢素(CSA)治疗小儿获得性重型再生障碍性贫血的疗效。方法计算机检索2001—2012年关于ATG联合CSA治疗小儿获得性重型再生障碍性贫血的随机对照试验,对符合质量标准的研究进行Meta分析。结果共纳入7个研究,Meta分析显示:ATG联合CSA与单用CSA治疗小儿获得性重型再生障碍性贫血1年以上生存率、总有效率、基本治愈率和复发率比较,其差异均有统计学意义[RR(95%CI)分别为1.3(1.01～1.68)、1.76(1.39～2.22)、2.18(1.28～3.69)和0.19(0.05～0.68)]。结论现有研究显示,ATG联合CSA的免疫抑制治疗方案对小儿重型再生障碍性贫血的治疗效果明显,其基本治愈率、总有效率、1年以上生存率等均优于单用CSA方案,且复发率也低于后者。
[Objective]To evaluate the effectiveness of combined therapy with antithymocyte globulin（ATG） and ciclosporin A（CSA） in pediatric patients with acquired severe aplastic anemia.[Methods]The randomized controlled trials（RCTs） about combined therapy with ATG and CSA in pediatric patients with acquired severe aplastic anemia,which were published during 2001-2012,were searched.Studies meeting the quality standard were investigated by Meta analysis.[Results]A total of 7 trials were involved.Meta analysis showed that there were significant differences in one-year survival rate,total effective rate,basic cure rate and recurrence rate between combined therapy with ATG and CSA and CSA alone therapy,while the RR value（95% CI） were 1.3（1.01-1.68）,1.76（1.39-2.22）,2.18（1.28-3.69） and 0.19（0.05-0.68）,respectively.[Conclusion]The current evidences show that the combined therapy with ATG and CSA has significant therapeutic effect in pediatric patients with acquired severe aplastic anemia,and its basic cure rate,total effective rate and one-year survival rate are all superior to those of CSA alone therapy,while the recurrence rate is lower.
出处
《职业与健康》
CAS
2013年第10期1195-1198,共4页
Occupation and Health
